2.60 -0.23 (-8.36%)
ENMD
| Trade ENMD now with |
Stock Details
Last Trade:2.60 Change:-0.23 (-8.36%) Prev Close:2.83 Open: 2.75 Days Range:2.52 – 2.79 52 Week Range: 0.90 - 5.57 Volume:114255 P/E: N/AEPS:-0.40
View AllRecent Alerts 02/07/12
Recent Alert on 02/06/12 at 7:01am
EntreMed (ENMD) Enters $9.3M of Strategic Financing, Two Board Members Resign
EntreMed (ENMD) Enters $9.3M of Strategic Financing, Two Board Members Resign
EntreMed, Inc. (Nasdaq: ENMD), has received approximately $9.3 million in strategic financing, as previously announced on January 23, 2012. The Company expects to receive the remaining funds on or about February 10, 2012. The financing was led by... Read More
Recent Alert on 02/06/12 at 7:01am
EntreMed (ENMD) Enters $9.3M of Strategic Financing, Two Board Members Resign
EntreMed (ENMD) Enters $9.3M of Strategic Financing, Two Board Members Resign
Recent Alert on 01/26/12 at 1:36pm
Unuasual 11 Midday Movers 01/26: (VIST) (MITI) (RNWK) (ENMD) Higher; (MNTA) (CRR) (MWW) Lower
Unuasual 11 Midday Movers 01/26: (VIST) (MITI) (RNWK) (ENMD) Higher; (MNTA) (CRR) (MWW) Lower
Recent Alert on 01/26/12 at 11:13am
Morning Movers 01/26: (MITI) (RNWK) (NFLX) (PMTC) Higher; (MNTA) (MWW) (LOGI) (CRR) Lower
Morning Movers 01/26: (MITI) (RNWK) (NFLX) (PMTC) Higher; (MNTA) (MWW) (LOGI) (CRR) Lower
Recent Alert on 01/23/12 at 7:04am
EntreMed (ENMD) Enters $10M in Purchase Agreements; Will Issue Convertible Notes
EntreMed (ENMD) Enters $10M in Purchase Agreements; Will Issue Convertible Notes
View AllRecent Press Releases
Press Release on 02/06/12 at 7:00am
Biotech Leaders Wei-Wu He, Ph.D and Tak W. Mak, Ph.D Join EntreMed's Board of Directors
Biotech Leaders Wei-Wu He, Ph.D and Tak W. Mak, Ph.D Join EntreMed's Board of Directors
View AllRecent SEC Filings
View AllRecent Blog Posts
Blog Posts on 09/12/10 at 9:39am
China Biotech Week in Review: Shanghai Pharma Plans $1.2 Billion IPO
China Biotech Week in Review: Shanghai Pharma Plans $1.2 Billion IPO
Blog Posts on 09/12/10 at 6:39am
EntreMed Sweetens Private Placement With China Rights to Cancer Drug
EntreMed Sweetens Private Placement With China Rights to Cancer Drug


